GlassScriptPhysician profile
Kashyap B Patel
NPI 1578675104
$378,521.80
in general payments reported to CMS, 2019-2025
93 companies · $56K in 2025
The $56K reported for 2025 was more than what 97% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $146K · 2020: $53K · 2021: $32K · 2022: $31K · 2023: $44K · 2024: $16K · 2025: $56K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $51K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $37K · Food and Beverage: $14K · Travel and Lodging: $8,866 · Honoraria: $2,500 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,016 · Education: $201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $51,450.83 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $37,370.64 |
| Food and Beverage | $14,244.76 |
| Travel and Lodging | $8,865.58 |
| Honoraria | $2,500.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,015.70 |
| Education | $200.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $69,151.06 | 2019-2025 | |
| Secura Bio, INC. | $49,086.13 | 2019-2024 | Copiktra |
| Sobi, INC | $40,056.50 | 2021-2025 | |
| Pfizer INC. | $26,627.97 | 2019-2025 | |
| Eli Lilly and Company | $21,425.00 | 2020-2023 | |
| Amgen INC. | $18,292.65 | 2019-2023 | Vectibix, Lumakras |
| Coherus Oncology, INC. | $15,652.46 | 2020-2023 | |
| E.R. Squibb & Sons, L.L.C. | $14,698.97 | 2019-2025 | Reblozyl, Opdivo, Breyanzi |
| Astrazeneca Pharmaceuticals LP | $13,960.97 | 2019-2025 | Tagrisso, Calquence, Imfinzi |
| Ge Healthcare | $13,082.00 | 2019 | |
| Sandoz INC. | $12,888.58 | 2019-2025 | Ziextenzo, Cyclophosphamide |
| Merck Sharp & Dohme LLC | $11,596.09 | 2019-2024 | Keytruda, Lynparza, Reblozyl |
| Janssen Biotech, INC. | $8,428.37 | 2019-2025 | Darzalex, Rybrevant, Carvykti |
| Glaxosmithkline, LLC. | $6,075.57 | 2020-2025 | Jemperli, Zejula, Shingrix |
| Genentech USA, INC. | $4,921.70 | 2019-2024 | Tecentriq, Kadcyla, Avastin |
Show all 93 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,482.09 | 2019-2025 | |
| Partner Therapeutics, INC. | $4,440.00 | 2019-2020 | |
| Illumina, INC. | $3,558.35 | 2022 | |
| Oxford Gene Technology INC | $2,957.89 | 2023 | |
| Dova Pharmaceuticals | $2,535.44 | 2019-2021 | |
| Fresenius Kabi USA, LLC | $2,494.08 | 2021-2024 | Stimufend |
| Janssen Global Services, LLC | $2,335.00 | 2023 | Carvykti, Darzalex |
| Cti Biopharma Corp. | $2,122.10 | 2022-2023 | Vonjo |
| Taiho Oncology, INC. | $2,119.15 | 2019-2024 | |
| Advanced Accelerator Applications | $1,891.32 | 2020 | |
| Seagen INC. | $1,738.99 | 2019-2023 | Padcev, Adcetris |
| Daiichi Sankyo INC. | $1,676.08 | 2019-2025 | Enhertu, Datroway |
| Asd Specialty Healthcare, LLC | $1,574.38 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $1,474.83 | 2019-2025 | |
| Pharmacosmos Therapeutics INC. | $1,434.16 | 2021-2025 | Monoferric |
| Celgene Corporation | $968.95 | 2021-2025 | Reblozyl, Pomalyst, Opdualag |
| Johnson & Johnson Health Care Systems INC. | $949.94 | 2021-2025 | Darzalex, Rybrevant, Akeega |
| Eisai INC. | $918.69 | 2019-2024 | |
| Athenex Pharmaceutical Division, LLC | $867.39 | 2019 | |
| Beigene USA, INC. | $727.53 | 2021-2023 | Brukinsa |
| Astrazeneca Uk Limited | $685.00 | 2023 | |
| Foundation Medicine, INC. | $565.06 | 2020-2023 | |
| Sun Pharmaceutical Industries INC. | $552.86 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $525.23 | 2019-2025 | Alunbrig, Iclusig, Ninlaro |
| Janssen Scientific Affairs, LLC | $491.60 | 2021-2024 | Rybrevant |
| Intrinsiq Specialty Solutions, INC. | $482.12 | 2022-2025 | |
| Cardinal Health 110 LLC | $465.00 | 2023-2024 | |
| Astellas Pharma US INC | $402.08 | 2019-2022 | |
| Roche Diagnostics Corporation | $389.83 | 2020-2021 | |
| Lilly USA, LLC | $381.10 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Fennec Pharmaceuticals, INC. | $379.90 | 2024-2025 | Fyarro, Pedmark |
| Adaptive Biotechnologies Corporation | $329.30 | 2021-2025 | Clonoseq |
| Regeneron Healthcare Solutions, INC. | $316.35 | 2021-2025 | Libtayo, Lynozyfic |
| Genentech, INC. | $281.39 | 2021 | |
| Spectrum Pharmaceuticals INC. | $266.19 | 2023-2025 | Rolvedon |
| Exelixis INC. | $262.48 | 2019-2024 | Cabometyx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $248.67 | 2021-2025 | Gilotrif |
| Gilead Sciences, INC. | $248.57 | 2021-2024 | Trodelvy |
| Karyopharm Therapeutics INC. | $226.88 | 2020-2023 | Xpovio |
| Ipsen Biopharmaceuticals, INC | $216.88 | 2021-2024 | Onivyde, Somatuline Depot |
| Morphosys, US INC. | $213.83 | 2021-2022 | |
| Organon LLC | $212.15 | 2022 | |
| Celltrion USA INC. | $211.48 | 2023-2024 | Vegzelma |
| Bayer Healthcare Pharmaceuticals INC. | $201.13 | 2019-2020 | |
| Kite Pharma, INC. | $200.35 | 2021-2024 | Yescarta |
| Stemline Therapeutics INC. | $197.01 | 2023 | Orserdu |
| Incyte Corporation | $170.75 | 2019-2025 | Jakafi, Zynyz, Monjuvi |
| Abbott Laboratories | $168.74 | 2022 | |
| Puma Biotechnology, INC. | $168.16 | 2019-2025 | |
| Array Biopharma INC | $158.60 | 2020-2025 | Braftovi, Lorbrena, Mektovi |
| Novocure INC. | $144.16 | 2024-2025 | Optune Lua (Novottf-200t), Optune |
| Heron Therapeutics, INC. | $142.35 | 2019-2025 | Cinvanti |
| Pharmaessentia USA Corporation | $119.73 | 2022-2024 | Besremi |
| Jazz Pharmaceuticals INC. | $119.38 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $109.82 | 2022-2024 | Soliris |
| Epizyme, INC. | $97.88 | 2021-2022 | |
| Servier Pharmaceuticals LLC | $90.42 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $84.75 | 2023 | |
| Avyxa Pharma, LLC | $73.12 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $72.23 | 2021-2023 | Imbruvica |
| Acrotech Biopharma INC. | $71.21 | 2022-2023 | Beleodaq |
| Menarini Silicon Biosystems, INC. | $69.07 | 2022 | |
| Kyowa Kirin, INC. | $68.07 | 2022-2023 | Poteligeo |
| Mylan Institutional INC. | $67.78 | 2019-2021 | |
| Deciphera Pharmaceuticals INC. | $48.01 | 2022-2023 | Qinlock |
| Mirati Therapeutics, INC. | $46.57 | 2023 | Krazati |
| Tolmar Pharmaceuticals, INC. | $33.96 | 2022 | |
| Rigel Pharmaceuticals, INC. | $31.04 | 2022-2024 | Rezlidhia, Tavalisse |
| Cycle Pharmaceuticals INC | $26.39 | 2025 | Phyrago |
| Verastem, INC. | $25.45 | 2019 | |
| Eusa Pharma (US) LLC | $24.45 | 2022 | |
| G1 Therapeutics, INC. | $23.14 | 2023 | Cosela |
| Emd Serono, INC. | $21.85 | 2023 | Bavencio |
| Agios Pharmaceuticals, INC. | $21.38 | 2019 | |
| Adc Therapeutics America, INC. | $16.55 | 2022 | |
| Shire North American Group INC | $16.28 | 2019 | |
| Aveo Pharmaceuticals, INC. | $15.75 | 2022 | |
| Janssen Pharmaceuticals, INC | $11.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$9,083.06 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kashyap Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.